Last reviewed · How we verify
NCT06887985
JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
NA trial testing JY231 Injection in Autoimmune Diseases in 45 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | He Huang |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 31 March 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- JY231 Injection
Conditions studied
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
Sponsor
He Huang — full company profile →
Who can join
Adults 18 to 75, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with Refractory Autoimmune Diseases (ADs). It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of Refractory Autoimmune Diseases (ADs).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4 -
<i>In Vivo</i> CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation.
Hao L, Lu J, Xue J. · · 2026 · PMID 42065060 · DOI 10.32604/or.2026.076420
Verify or expand the search:
- PubMed search for NCT06887985
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JY231 Injection
Trials testing the same drug.
- NCT06902025 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · NA · not yet recruiting
- NCT06797024 — JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders · NA · recruiting
- NCT06689917 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
- NCT06678282 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
Other recruiting trials for Autoimmune Diseases
Currently open trials in the same condition.
- NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
Other He Huang trials
Trials by the same sponsor.
- NCT06902025 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · NA · not yet recruiting
- NCT06785519 — CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis · EARLY_PHASE1 · recruiting
- NCT06709131 — A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · suspended
- NCT06571825 — RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR · Phase 4 · recruiting
- NCT06120166 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06887985 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by He Huang
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06887985.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing